MedTrace Logo

Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma

NCT06025162 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-09-06

No results posted yet for this study

Summary

Venous thromboembolism (VTE) causes up to 100,000 deaths annually. Between 10%-30% of patients die within one month of VTE diagnosis, while survivors remain at increased risk for VTE recurrence or other complications like post-thrombotic syndrome or chronic pulmonary hypertension in the following decade. Trauma patients have many risk factors that predispose them to a VTE. During the first 48 hours after blunt trauma, patients are prothrombotic due to the release of procoagulant factors, have excessive thrombin generation due to extensive tissue and vascular injury, and have reduced circulation of endogenous anticoagulants like protein C.

Conditions

  • Thromboembolism, Venous

Interventions

DRUG

enoxaparin

dose of enoxaparin at 48 hours post-VTE prophylaxis initiation

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Tamara Reiter, PharmD · Methodist Health System

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2024-08-31
Completion
2024-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06025162 on ClinicalTrials.gov